Designer benzodiazepines, including flualprazolam and flubromazolam, are clandestinely delivered to circumvent federal controls. Although flualprazolam and flubromazolam are fundamentally comparative to alprazolam, they do not have an endorsed medical sign. Flualprazolam differs from alprazolam by the expansion of a single fluorine particle. While, flubromazolam varies by the addition of a single fluorine particle and substitution of a bromine for a chlorine molecule. The pharmacokinetics of these designer compounds has not been extensively evaluated. Within the show consider, we evaluated flualprazolam and flubromazolam in a rat show and compared the pharmacokinetics of both compounds to alprazolam. Twelve male, Sprague-Dawley rats were given a 2 mg/kg subcutaneous dose of alprazolam, flualprazolam and flubromazolam and plasma pharmacokinetic parameters were assessed. Both compounds shown significant two-fold increments in volume of dissemination and clearance. The discoveries of this study show that fluorination of the alprazolam pharmacophore increments pharmacokinetic boundaries including half-life and volume of appropriation. Flualprazolam and flubromazolam's rise in these parameters increases the body's overall exposure and increases the risk of greater toxicity than alprazolam.
Share this article